BidaskClub Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold

Amicus Therapeutics (NASDAQ:FOLD) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, January 9th.

Other analysts also recently issued reports about the stock. Leerink Swann restated a “buy” rating and issued a $20.00 target price (up from $17.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Bank of America upped their price target on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 4th. Chardan Capital reiterated a “buy” rating and set a $18.50 price target (up from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Tuesday, October 10th. Finally, Goldman Sachs Group reiterated a “neutral” rating and set a $17.00 price target on shares of Amicus Therapeutics in a report on Friday, October 6th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $18.31.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded down $0.25 during midday trading on Tuesday, reaching $15.90. 2,810,000 shares of the company’s stock were exchanged, compared to its average volume of 2,260,000. Amicus Therapeutics has a one year low of $5.07 and a one year high of $16.60. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. The company has a market cap of $2,600.00, a P/E ratio of -8.69 and a beta of 1.72.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business had revenue of $10.90 million during the quarter, compared to the consensus estimate of $9.02 million. During the same quarter last year, the firm earned ($0.33) earnings per share. The business’s quarterly revenue was up 419.0% on a year-over-year basis. equities analysts anticipate that Amicus Therapeutics will post -1.52 earnings per share for the current fiscal year.

In related news, insider Jay Barth sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $13.59, for a total transaction of $67,950.00. Following the completion of the transaction, the insider now owns 69,184 shares in the company, valued at approximately $940,210.56. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Daphne Quimi sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $14.72, for a total transaction of $117,760.00. Following the transaction, the senior vice president now owns 62,676 shares of the company’s stock, valued at approximately $922,590.72. The disclosure for this sale can be found here. Insiders sold a total of 197,890 shares of company stock valued at $2,767,181 in the last ninety days. Corporate insiders own 3.40% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Strs Ohio bought a new position in shares of Amicus Therapeutics during the 3rd quarter worth approximately $102,000. Birchview Capital LP acquired a new position in Amicus Therapeutics during the 3rd quarter valued at approximately $151,000. Sage Capital Advisors llc acquired a new position in Amicus Therapeutics during the 3rd quarter valued at approximately $154,000. Engineers Gate Manager LP acquired a new position in Amicus Therapeutics during the 3rd quarter valued at approximately $155,000. Finally, Tudor Investment Corp ET AL acquired a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $124,000.

ILLEGAL ACTIVITY WARNING: “BidaskClub Downgrades Amicus Therapeutics (NASDAQ:FOLD) to Hold” was published by Week Herald and is owned by of Week Herald. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://weekherald.com/2018/01/20/bidaskclub-lowers-amicus-therapeutics-fold-to-hold.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply